Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.49 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.49 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19823010 | 0.91 | GSK3B (0.61) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL12719169 | 0.85 | MAPT (0.58) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL541208 | 0.84 | GSK3B (1.00) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL50003 | 0.84 | GSK3B (0.71) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL7025664 | 0.84 | GSK3B (0.71) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL19844452 | 0.84 | GSK3B (0.54) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL11379783 | 0.84 | HDAC1 (0.57) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| Hydrochloric Acid SCHEMBL6538348 | 0.83 | GSK3B (0.69) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL1978734 | 0.81 | GSK3B (0.67) | GSK3BALDH1A1HPGDKDM4EALOX15 | |
| SCHEMBL10704692 | 0.81 | GSK3B (0.67) | GSK3BALDH1A1HPGDKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | GSK3B 961/4885ALDH1A1 3519/4885HPGD 1218/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | GSK3B 961/4885ALDH1A1 3519/4885HPGD 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.